Search Results

Kenakin and Hoare on '   Applying Pharmacology to Drug Discovery ' and ' Advanced Data Analysis for GPCR Pharmacology .' Dates:  September 5 to 26, 2024 What You’ll Learn during the four sessions: How to measure pharmacologic for their work on GPCR pharmacogenomics  Let’s dive into the   Classified GPCR News  from August 5th nanobodies on GPCR structural biology and their potential as therapeutic agents Industry News Nxera Pharma

🚨 Hurry to reserve your spot for the Principles of Pharmacology I & II BUNDLE before the Early Every Thursday at 10 AM EST: Principles of Pharmacology I Dates: October 3, 10, 17, 24 (four sessions ) Topics: Pharmacologic activity measurement, mechanisms of action, and GPCR discovery strategies. Registration deadline: September 27, 2024 Principles of Pharmacology II Dates: October 31, November 𝗦𝘂𝗺𝗺𝗮𝗿𝘆 𝗼𝗳 𝘁𝗵𝗲 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 𝗼𝗳 𝗔𝗘𝗙𝟬𝟭𝟭𝟳 𝗣𝗵𝗮𝘀𝗲 𝟮𝗯 𝗶𝗻 𝗖𝗨𝗗 Nxera Pharma

In this lesson, you'll gain: ✅ Clarity on what “irreversible” really means  in kinetic and pharmacologic Kenakin Content trusted by biotech, pharma, and academia 💎 $2999/year — one conference cost = a full Here , you’ll get: Weekly lectures  that sharpen your command of how enzyme activity drives pharmacokinetics

hormone recognition and distinctive Gq protein coupling by the kisspeptin receptor Industry News Nxera Pharma , 2024 | 11th Adhesion GPCR Workshop July 12 - 17, 2026 | 20th World Congress of Basic and Clinical Pharmacology 2026 GPCR Jobs NEW Scientist; Biochemistry, Cellular and Mechanistic Pharmacology; Lead Discovery and Director GPCR Drug Discovery Biologist HIGHLIGHT Principal Scientist, In vitro pharmacology Post-Doctoral Scientist- Molecular Pharmacology (FDE) Research Assistant Senior Scientist - Receptor Pharmacology

Pharmacology isn’t only about ligands, receptors, and downstream G protein signaling—it’s also about Clarify whether observed effects reflect true pharmacology or assay artifacts . From Bench Insight to Strategic Advantage Terry Kenakin’s decades of pharmacology leadership converge Kenakin Content trusted by biotech, pharma & academia 💎 $2999/year — one conference cost = a full A growing on-demand library  of expert pharmacology lessons to revisit anytime.

December 2021 Perkins’ Head of Molecular Endocrinology and Pharmacology, Professor Kevin Pfleger, was appointed President of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists Coincidentally, on the same day, Prof Pfleger was announced as a Fellow of the British Pharmacological ASCEPT is the peak professional society devoted to advancing excellence in Clinical and Experimental Pharmacology Established in 1966, ASCEPT is affiliated with the International Union of Basic and Clinical Pharmacology

transduction at GPCRs: Allosteric activation of the ERK MAPK by β-arrestin GPCR Binders, Drugs, and more Pharmacologically Proof-of-Concept Studies Sosei Heptares’ President & CEO Chris Cargill Wins Executive of the Year at the Citeline Pharma Chemotactic Cytokines GPCR Jobs Head of Human Resource Business Partners Senior Scientist, In vitro pharmacology - Crinetics Pharmaceuticals Senior Director, In vitro pharmacology - Crinetics Pharmaceuticals In vivo Antibody Discovery Research Scientist In Vitro Biologist/Molecular Pharmacologist Senior Vice President

It's spring break at Dr. GPCR — a quieter week, and a good moment to look at what this community is examining next. Five live Masterclasses are scheduled before summer break. Two Partner Webinars are lining up. And two recent sessions are moving into the on-demand library next week. Taken together, the lineup spans biophysics, kinetics, spatial biology, subcellular regulation, and program building. Five sessions examining GPCR science past the equilibrium snapshots, where and when receptors signal, how kinetics shape drug action, and how all of it translates into programs. Coming to the GPCR Masterclass On-Demand Library Two sessions from April are moving into the Premium Masterclass library next week: Bryan Roth on intracellular allosteric modulators as molecular glues — recorded April 9. Terry Hébert on iPSC-derived systems for GPCR signaling and translation — recorded April 16. Explore the library ➤ Five Live GPCR Masterclasses Before Summer All included in Premium , each one a direct scientific exchange with a leading scientist, with full replay access afterward. Sam Hoare  — How Signaling Kinetics Shapes GPCR Drug Action. May 14. Sudarshan Rajagopal  — The Spatiotemporal Revolution in GPCR Biology. May 21. Andrew Tobin  — How to Build Breakthrough GPCR Programs. June 4. Jakob Höppner  — Subcellular Regulation of PTH1R Signaling. June 11. Dmitry Veprintsev  — Biophysical Approaches to Study Orphan GPCR Ligand Binding and Signalling. June 18. More live Masterclasses coming in the fall. Learn more about Live Masterclasses ➤ Partner Webinars Eurofins DiscoverX (Dr. Terry Kenakin, invited speaker)  — Biased signaling. GeneTex (Dr. Alex Ball)  — A reagent gap that holds back the biology. Details coming soon. Next Week in Boston The Dr. GPCR community gathers in person next week. GPCRs Targeted Drug Discovery Summit  — April 28–30. What to expect and how to register ➤ GPCR Happy Hour  — April 29. Come find us ➤ About Dr. GPCR Dr. GPCR is the intelligence and community for GPCR scientists. Premium members have full access to the pre-summer Masterclass lineup, the live sessions, and the expanding on-demand library. Where to find your Premium content As a Premium member, everything is under the Premium  menu in the top navigation — Live Masterclass, Masterclass On Demand, Weekly News, Job Listings, GPCR Events, Ask the Ecosystem, Ecosystem Members, and Your Feedback. Bookmark ecosystem.drgpcr.com  and you're one click away from all of it. Join Premium ➤ Try Premium for 14 days — $49 ➤

November 2021 Addex's strategic partner The Janssen Pharmaceutical Companies of Johnson & Johnson, Inc Switzerland, November 15, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical pioneering allosteric modulation-based drug discovery and development, today announced that Janssen Pharmaceuticals , Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, has successfully completed

Boston, MA and Irvine, CA — [March 18, 2026]  — Dr. GPCR, a nonprofit organization serving the global G protein-coupled receptor (GPCR) research community through education, curated scientific content, and community engagement, today announced a strategic media partnership with GeneTex, a multinational antibody manufacturer with long-standing expertise in reagent development and validation. Anti-GPCR antibody specificity has been a persistent challenge in the field — one with real consequences for data reproducibility. This partnership exists to bring that conversation into the open, and to invite GPCR researchers to be part of the solution. GeneTex is offering free antibody samples to the community — not as a promotion, but as a direct scientific challenge That challenge is well recognized: the specificity and reliability of anti-GPCR antibodies, and the downstream impact these limitations have on the reproducibility of GPCR-related data. Given the structural complexity and dynamic nature of GPCRs, generating antibodies that selectively and consistently recognize their intended targets remains a significant technical challenge. Concerns around antibody specificity are not merely theoretical. When antibodies fail to selectively recognize GPCR targets, the resulting data can be difficult to reproduce. These challenges have contributed to ongoing debate within the field regarding how antibody-based data should be interpreted and contextualized in GPCR research and GPCR drug discovery. This partnership seeks to bring those challenges into clearer scientific focus by placing GeneTex’s GPCR-focused antibody efforts within an open, community-wide conversation. The collaboration reflects a shared recognition that improving data reproducibility in GPCR biology requires continued attention to antibody specificity, validation strategies, and transparent discussion of limitations. GeneTex is developing a comprehensive portfolio of recombinant antibodies targeting human non-sensory and orphan GPCRs. These efforts are supported by characterization approaches that include knockout/knockdown testing, endogenous receptor detection, and comparative analyses. Through this partnership, GeneTex’s antibody portfolio is introduced to the GPCR community as part of a broader discussion about how antibody quality influences data reliability and reproducibility. Researchers working on GPCR targets are invited to request free samples through the Dr. GPCR partnership page, evaluate the antibodies in their own experimental systems, and share their findings — positive or negative. Community feedback is central to how this partnership is designed to work. “Challenges around anti-GPCR antibody specificity have real consequences for the reproducibility of GPCR data,” said Dr. Yamina Berchiche , Founder and CEO of Dr. GPCR. “As a nonprofit organization, our role is not to validate reagents, but to ensure that these issues are openly discussed and scientifically contextualized. This partnership reflects our commitment to advancing conversations that directly affect how GPCR research is conducted and interpreted.” “GPCRs present unique challenges for antibody development,” said Alexander Ball, Jr., M.D., Senior Scientist at GeneTex. “We see value in situating our antibody efforts within an open scientific dialogue focused on specificity, reliability, and the reproducibility of the data generated using these tools. Thorough validation and engagement with the GPCR researcher community are both essential for realizing our goal of producing trusted antibody reagents for GPCR biologists.” For the GPCR research community, the relevance of this partnership extends beyond individual reagents. Reproducible data are foundational to progress in GPCR biology, target validation, and translational research. When antibody specificity is uncertain, variability in experimental outcomes can propagate across studies, complicating interpretation and slowing progress. By explicitly acknowledging these challenges, the partnership aligns with broader efforts across the life sciences to improve data reproducibility by addressing limitations at the level of research tools. It reinforces the importance of transparency and community engagement in strengthening the experimental foundations that support GPCR research and GPCR drug discovery. Together, Dr. GPCR and GeneTex aim to support informed, critical dialogue around anti-GPCR antibody specificity and the reproducibility of GPCR data, contributing to a more robust and reliable foundation for the field. About Dr. GPCR Dr. GPCR is a nonprofit organization connecting the global GPCR community through training, curated scientific news, expert-led courses, and networking. Through educational programs, media initiatives, and a growing partner ecosystem, Dr. GPCR supports scientists and organizations advancing GPCR biology and GPCR-targeted drug discovery. About GeneTex GeneTex is a multinational antibody manufacturer founded in 1997, with research and manufacturing operations across the United States, Taiwan, and Europe. GeneTex develops antibodies and reagents supporting a broad range of biomedical research areas, with ongoing efforts focused on recombinant monoclonal anti-GPCR antibodies targeting human GPCRs using rigorous characterization approaches. To learn more about the Dr. GPCR–GeneTex partnership, visit: GeneTex Partnership Page

Andrew Tobin for an incredible week filled with prestigious events, including receiving the British Pharmacological and TPD Structural Biology Platforms GPCR Events, Meetings, and Webinars December 10 - 12, 2024 | Pharmacology to GPCR Drug Discovery March 12 - 14, 2025 | NextGen Biomed 2025 March 25 - 28, 2025 | 10th German Pharm-Tox GPCR Jobs GPCR Molecular Pharmacologist Scientist - Biology Scientist I Cell Biology - Tectonic Therapeutic Research Associate - Professor Graeme Milligan Postdoc in Molecular Pharmacology - The Hauser Group

Terry Kenakin's "Applying Pharmacology to Drug Discovery" course at Dr. to advance novel anti-CCR8 antibody  for cancer immunotherapy Novo Holdings Portfolio Company Amolyt Pharma , 2024 | 11th Adhesion GPCR Workshop July 12 - 17, 2026 | 20th World Congress of Basic and Clinical Pharmacology Research Unit Postdoctoral Scholar – Synaptic physiology, optical imaging, substance use disorder, pharmacology Research Fellow Postdoctoral Fellow – Molecular Pharmacology of Feeding Behavior Director of Laboratory

Webinar - Antiverse: Engineering the Future of Drug Discovery (March 30, 2023) NEW Molecular Dynamics in Pharma (June 4 - 8, 2023). 2023 Molecular Pharmacology (GRS) Seminar GRC. (June 10 - 11, 2023). Adrenoceptors and GPCR Signalling (June 30 - July 1, 2023) 19th World Congress of Basic & Clinical Pharmacology IRN I-GPCRNet (October 25 - 27, 2023) GPCR Jobs NEW Team Lead protein production and profiling NEW Pharmacologist

Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290 Crinetics Pharmaceuticals Treatment Of Congenital Adrenal Hyperplasia (CAH) And Acth-Dependent Cushing’s Syndrome (ADCS) Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals CB1 receptor inverse agonist , 2024 | 11th Adhesion GPCR Workshop July 12 - 17, 2026 | 20th World Congress of Basic and Clinical Pharmacology 2026 GPCR Jobs HIGHLIGHT Principal Scientist, In vitro pharmacology Senior Scientist - Receptor Pharmacology

Thrilling beginning to Principles of Pharmacology I We are excited to announce the start of our Principles of Pharmacology I course! Don’t miss this opportunity to advance your knowledge and skills in pharmacology! Modules: October 31st : The Eyes to See- The Importance of Pharmacologic Assays. Multi-Target Collaboration with Novartis to Discover and Develop Protein Therapeutics with Generative AI Nxera Pharma

Samuel Hoare on Advanced data analysis for GPCR pharmacology, which will be held on Thursdays between , Mark Schmeizl, had a great conversation about this position with Beth Fleck, Director of In Vitro Pharmacology at Crinetics Pharmaceuticals! MacDonald as Chief Executive Officer Nxera Pharma Announces Exclusive Supply and Distribution Agreement 2026 GPCR Jobs NEW Postdoc Position Principal Scientist, In vitro pharmacology Senior Associate Scientist

Hello Dr.GPCR readers! This is Lucía from the Celtarys Research chemistry team.  For our very first post in this ecosystem, we wanted to highlight a huge part of our work at Celtarys Research: conjugation strategies. You can check what we do here on our website!   Conjugation strategies for small molecules are very versatile! In this case, we would like to focus on the synthesis of fluorescent probes. Traditionally, the most reliable and commonly used method is the amide coupling  using acid and amine .[ 1 ] This method has several advantages: it is usually very robust, good yields, reagents are found in most chem labs (like HATU, HoBT, EDCI etc.). Still, there are some downsides, such as the byproduct obtained by the O-acylisourea rearranging intramolecularly into the N-acylurea.[ 2]     NHS ester amide coupling  is the most suited for bioconjugation with proteins, DNA, etc, thanks to its reaction with the free amino groups present in these biomolecules. NHS esters are not very stable even in aqueous environment but they only need a slightly basic medium for the reaction to work, so they have to be used quickly and stored correctly. Not only do they work in aqueous medium, but also in aprotic solvents like DMF, where you will need to add a base such as TEA. [ 3]     Maleimide  conjugation with thiols  present Cys residues. This conjugation is very useful for tagging biomolecules and can also be used to develop fluorescent probes with small molecules. Its biggest advantage is the presence of Cys residues in proteins, although sometimes S-S bridge reduction is needed, and how quickly the reaction takes place. The biggest detractor? It’s reversible under non-reducing conditions. [ 4]     Other strategies include click chemistry,  more specifically, the CuAAC (Cu(I)- catalyzed azide-alkyne 1,3-dipolar cycloaddition), which is a very robust conjugation strategy to obtain linkers with a rigid moiety (the triazol). But it also presents some issues, such as synthesizing the as the presence of the copper catalyst, which has to be removed completely, otherwise it can quelate biomolecules or induce cell toxicity. [ 5]     At Celtarys’ we have our conjugation strategy - our own proprietary technology- which bypasses some of the issues seen before. There’s no need for any catalysts; all reagents will be incorporated in the structure of the final compound. The reaction is convergent, efficient and robust. Thanks to the unique linker structure we obtain, which can be divided into three differentiated parts, we can modify the rigidity of the linker as well as the physicochemical properties of the whole probe. This property comes from the wide chemical space this reaction can access – we can substitute one reagent and make an unprecedented combination, also using commercially available precursor, which improves the performance of the probes.  It also poses some disadvantages – just like acid-amine amide coupling, some byproducts are obtained during the synthesis. However, these are usually easily removable. Besides, it’s an eco-friendlier method, which always helps future-proof our probes!  References   (1) Brown, D. G.; Boström, J. Analysis of Past and Present Synthetic Methodologies on Medicinal Chemistry: Where Have All the New Reactions Gone?: Miniperspective. J. Med. Chem.   2016 , 59  (10), 4443–4458. https://doi.org/10.1021/acs.jmedchem.5b01409 .   (2) Sam, S.; Touahir, L.; Salvador Andresa, J.; Allongue, P.; Chazalviel, J.-N.; Gouget-Laemmel, A. C.; Henry De Villeneuve, C.; Moraillon, A.; Ozanam, F.; Gabouze, N.; Djebbar, S. Semiquantitative Study of the EDC/NHS Activation of Acid Terminal Groups at Modified Porous Silicon Surfaces. Langmuir   2010 , 26  (2), 809–814. https://doi.org/10.1021/la902220a .   (3) Fan, J.; Toth, I.; Stephenson, R. J. Chapter Three - Bioconjugated Materials in the Development of Subunit Vaccines. In Comprehensive Analytical Chemistry ; Verma, S. K., Das, A. K., Eds.; Elsevier, 2023; Vol. 103, pp 59–103. https://doi.org/10.1016/bs.coac.2023.02.005 .   (4) Fontaine, S. D.; Reid, R.; Robinson, L.; Ashley, G. W.; Santi, D. V. Long-Term Stabilization of Maleimide–Thiol Conjugates. Bioconjugate Chem.   2015 , 26  (1), 145–152. https://doi.org/10.1021/bc5005262 .   (5) Meldal, M.; Tornøe, C. W. Cu-Catalyzed Azide−Alkyne Cycloaddition. Chem. Rev.   2008 , 108  (8), 2952–3015. https://doi.org/10.1021/cr0783479 .

Is Your GPCR Program Slowing Down—Even With Good Data? You’re not alone. Most teams don’t stall because the science is weak. They stall because the data becomes a mess. I call it the Lego Bucket Problem : You’ve got CRO output, internal assay data, maybe even some promising signals. But there’s no blueprint. No structure. No clear path to your next milestone. Meetings drag. Decisions stall. And momentum quietly dies. The Hidden Cost of Good Science Without Systems I’ve seen this pattern again and again—across academia, biotech, and through close work with dozens of teams inside the Dr. GPCR Ecosystem. Strong science. Promising data. But no systems to turn it into momentum. Data arrives too fast and too fragmented CROs deliver output without clear integration Teams chase the wrong assays, too late to pivot Milestones slip—and nobody realizes until it’s too late Failing fast? Not possible when nothing’s built to surface the right  insights early. That’s Why I Built Yamina’s Consulting Corner This is not “advising.” This is embedded consulting for biotech and VC teams who need to move fast —without compromising scientific integrity. Unlike traditional advisors, I'm not just observing; I'm part of your team . This allows me to experience your challenges firsthand, identify roadblocks faster , and i mplement solutions from within , ensuring genuine buy-in and lasting momentum. Here’s what I bring: Biology-First Strategy I’ve designed GPCR assays, led collaborations across research environments, and translated complex data into action. I know how to ask the right scientific questions—and when to shift from analysis to execution. Systems That Drive Execution No more disconnected slides and 6-week meeting cycles. I install simple tools that surface insights, align your team, and keep momentum moving. True Embedded Partnership I review CRO scopes, flag risks early, and sit in on your strategic calls. I’m not watching from the sidelines—I’m driving with you. Real-Time Global Insight As founder of Dr. GPCR, I’m connected to 1,300+ scientists and decision-makers worldwide. That network gives me a constant pulse on what’s working—and what’s next. Who I Work With ✅ Biotech Teams  – Especially those lacking in-house GPCR leads or overwhelmed by CRO data chaos. ✅ Venture Capital Firms  – Looking to accelerate, troubleshoot, or validate GPCR assets in their portfolio. ✅ Contract Research Organizations (CROs)  – Wanting to better align with biotech clients and deliver real  insight, not just data. My Consulting Philosophy Every successful GPCR program is a blend of scientific excellence  and operational precision . One without the other will quietly kill your momentum. My work is rooted in: ✔️ Scientific Integrity ✔️ Operational Discipline ✔️ Collaborative Partnership Let’s Get Your GPCR Program Moving Again Whether you’re building from scratch or recovering from a stall, I’ll help you move faster—with fewer blind spots, tighter execution, and a clear line of sight to your next key decision. 🚀 Book your free 30-minute strategy call Let’s unlock the momentum your GPCR program needs. 👉 https://calendly.com/drgpcr/yamina-corner Or explore how we can work together: 👉 Yamina.org 🔑 Key Takeaways ✅ Even strong science stalls without operational structure ✅ Scattered data = missed insights = wasted time ✅ You can’t fail fas t if you can’t see the problems early ✅ Most teams don’t need more data— they need clarity ✅ Yamina’s Corner helps teams move from data chaos to decisive action ✅ This is hands-on support —not passive advising p.s: Still unsure if this is the right fit? Let’s talk through your program—no pitch, just clarity.

Every Thursday at 10 AM EST: Principles of Pharmacology I October 3, 10, 17, 24 (four sessions) Topics : Pharmacologic activity measurement, mechanisms of action, and GPCR discovery strategies. Principles of Pharmacology II October 31, November 7, 14, 21, December 5 (five sessions) (we skipped The Principles of Pharmacology I & II BUNDLE is your key to mastering the field. platform; Carterra Ultra™ ushers in a new frontier in fragment and small molecule drug discovery Is the pharma

Gunnar Schulte, Lukas Grätz, Pawel Kozielewicz, et al. for their study on Frizzleds act as dynamic pharmacological Samuel Hoare on Advanced data analysis for GPCR pharmacology, which will be held on Thursdays between and Pharmacology Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024 Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia 2026 GPCR Jobs NEW Principal Scientist, In vitro pharmacology Senior Associate Scientist - Global Research

Terry Kenakin's "Applying Pharmacology to Drug Discovery" course at Dr. pathways and two distinct high-affinity sites for succinate in succinate receptor 1/GPR91 Specific pharmacological development GPCR Events, Meetings, and Webinars March 13 - 15 | Biologics 2024 March 13 - 15 | 9th German Pharm-Tox , 2024 | 11th Adhesion GPCR Workshop July 12 - 17, 2026 | 20th World Congress of Basic and Clinical Pharmacology Research Fellow Postdoctoral Fellow – Molecular Pharmacology of Feeding Behavior Director of Laboratory

Samuel Hoare on Advanced data analysis for GPCR pharmacology, which will be held on Thursdays between Terry Kenakin’s Applying Pharmacology to Drug Discovery course. Continue to increase your knowledge of Pharmacology by joining this practical approach class today. Industry News Monash University pharmaceutical scientists honoured in NHMRC Research Excellence Awards Re-election of its Board and Executive Management Team and the Approval of Change of Company Name to Nxera Pharma

University We successfully started our Dr.GPCR University workshop, 'Advanced Data Analysis for GPCR Pharmacology Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2024 Crinetics Pharmaceuticals To Present Advancements 2026 GPCR Jobs Post Doctoral Fellow Postdoc Position Principal Scientist, In vitro Pharmacology Senior

GPCR University Course, ‘Applying Pharmacology to Drug Discovery,’ led by Dr. Research GPCR Events, Meetings, and Webinars March 13 - 15 | Biologics 2024 March 13 - 15 | 9th German Pharm-Tox , 2024 | 11th Adhesion GPCR Workshop July 12 - 17, 2026 | 20th World Congress of Basic and Clinical Pharmacology Research Unit Postdoctoral Scholar – Synaptic physiology, optical imaging, substance use disorder, pharmacology Research Fellow Postdoctoral Fellow – Molecular Pharmacology of Feeding Behavior Director of Laboratory

Celebrating Excellence:   Patrick Sexton  and Arthur Christopoulos  Named Among Top 1% of Scientists in Pharmacology Pfleger ,  Peter J McCormick , Cristina Salmerón ,   Paul A Insel PGxDB: an interactive web-platform for pharmacogenomics novo antibodies look more like drugs  GPCR Events, Meetings, and Webinars December 10 - 12, 2024 | Pharmacology to GPCR Drug Discovery March 12 - 14, 2025 | NextGen Biomed 2025 March 25 - 28, 2025 | 10th German Pharm-Tox Research Associate - Professor Graeme Milligan Postdoc in Molecular Pharmacology - The Hauser Group

GPCR University Last week marked the beginning of our first Dr.GPCR University course, 'Applying Pharmacology coupled receptor-mediated vasocontraction in rat coronary arteries GPCRs involved in metabolic diseases: pharmacotherapeutic Board of Directors GPCR Events, Meetings, and Webinars February 20, 2024 | Career Opportunities in Pharmacology and Drug Discovery March 13 - 15 | 9th German Pharm-Tox Summit March 23 - 24, 2024 | Ligand Recognition , 2024 | 11th Adhesion GPCR Workshop July 12 - 17, 2026 | 20th World Congress of Basic and Clinical Pharmacology

Pharmacological characterization of novel small molecule agonists and antagonists for the orphan receptor Multiple Myeloma Behind Friday's $161M IPO: A star scientist, GPCR drug discovery and a plan to challenge pharma (June 4 - 8, 2023). 2023 Molecular Pharmacology (GRS) Seminar GRC. (June 10 - 11, 2023). (June 11 - 16, 2023). 19th World Congress of Basic & Clinical Pharmacology 2023. PhD student at Department of Drug Design and Pharmacology Software / database development postdoc at

17th, 2024 Industry News Centessa Launches Phase 2 Trial of ORX750 for Narcolepsy and IH Crinetics Pharmaceuticals to GPCR Drug Discovery March 12 - 14, 2025 | NextGen Biomed 2025 March 25 - 28, 2025 | 10th German Pharm-Tox | BIO International Convention 2025 July 12 - 17, 2026 | 20th World Congress of Basic and Clinical Pharmacology Principal Scientist, Medicinal Chemistry PhD fellowship in GPCR mechanosensing Senior Scientist, GPCR Pharmacology Research Associate - Professor Graeme Milligan Postdoc in Molecular Pharmacology - The Hauser Group

GPCR University course, 'Applying Pharmacology to Drug Discovery,' led by Dr. and more Nanobody-Mediated Dualsteric Engagement of the Angiotensin Receptor Broadens Biased Ligand Pharmacology Pharmacological characterization and radiolabeling of VUF15485, a high-affinity small-molecule agonist and Drug Discovery March 13 - 15 | 9th German Pharm-Tox Summit March 23 - 24, 2024 | Ligand Recognition 2026 GPCR Jobs NEW Research Fellow NEW  Postdoctoral Fellow – Molecular Pharmacology of Feeding Behavior

with Domain Therapeutics and Université de Montréal for GPCR-Targeted Drug Discovery "Apr.19.2022 Ono Pharmaceutical